Differential Effects on Light Chain Amyloid Formation Depend on Mutations and Type of Glycosaminoglycans*
暂无分享,去创建一个
[1] R. Linhardt,et al. Divergent effect of glycosaminoglycans on the in vitro aggregation of serum amyloid A. , 2014, Biochimie.
[2] R. Kayed,et al. Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins. , 2014, Biochemical pharmacology.
[3] M. Ramirez-Alvarado,et al. Kinetic control in protein folding for light chain amyloidosis and the differential effects of somatic mutations. , 2014, Journal of molecular biology.
[4] Marina Ramirez-Alvarado,et al. Thermal Stability Threshold for Amyloid Formation in Light Chain Amyloidosis , 2013, International journal of molecular sciences.
[5] J. Buxbaum,et al. A molecular history of the amyloidoses. , 2012, Journal of molecular biology.
[6] A. Dispenzieri,et al. What do I need to know about immunoglobulin light chain (AL) amyloidosis? , 2012, Blood reviews.
[7] B. Volkman,et al. Tyrosine Residues Mediate Fibril Formation in a Dynamic Light Chain Dimer Interface , 2012, The Journal of Biological Chemistry.
[8] Jonathan A. Fauerbach,et al. Supramolecular non-amyloid intermediates in the early stages of α-synuclein aggregation. , 2012, Biophysical journal.
[9] M. Ramirez-Alvarado,et al. Glycosaminoglycans promote fibril formation by amyloidogenic immunoglobulin light chains through a transient interaction. , 2011, Biophysical chemistry.
[10] A. Dispenzieri,et al. Changes in serum‐free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis , 2011, American journal of hematology.
[11] V. Trinkaus-Randall,et al. Role of Glycosaminoglycan Sulfation in the Formation of Immunoglobulin Light Chain Amyloid Oligomers and Fibrils* , 2010, The Journal of Biological Chemistry.
[12] M. Ramirez-Alvarado,et al. Comparison of amyloid fibril formation by two closely related immunoglobulin light chain variable domains , 2010, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[13] B. Nordén,et al. Excited-State Properties of the Indole Chromophore. Electronic Transition Moment Directions from Linear Dichroism Measurements: Effect of Methyl and Methoxy Substituents , 2010 .
[14] P. Dubin,et al. Glycosaminoglycans as polyelectrolytes. , 2010, Advances in colloid and interface science.
[15] B. Volkman,et al. A single mutation promotes amyloidogenicity through a highly promiscuous dimer interface. , 2010, Structure.
[16] Baltazar Becerril,et al. A single mutation at the sheet switch region results in conformational changes favoring lambda6 light-chain fibrillogenesis. , 2010, Journal of molecular biology.
[17] M. Ramirez-Alvarado,et al. Structural alterations within native amyloidogenic immunoglobulin light chains. , 2009, Journal of molecular biology.
[18] Joseph Zaia,et al. Organ-specific Heparan Sulfate Structural Phenotypes* , 2009, Journal of Biological Chemistry.
[19] D. A. Fernández‐Velasco,et al. Thermodynamic and kinetic characterization of a germ line human lambda6 light-chain protein: the relation between unfolding and fibrillogenesis. , 2009, Journal of molecular biology.
[20] M. Ramirez-Alvarado,et al. Structural Insights into the Role of Mutations in Amyloidogenesis* , 2008, Journal of Biological Chemistry.
[21] V. Uversky,et al. Effect of methionine oxidation on the structural properties, conformational stability, and aggregation of immunoglobulin light chain LEN. , 2008, Biochemistry.
[22] B. Volkman,et al. Altered Dimer Interface Decreases Stability in an Amyloidogenic Protein* , 2008, Journal of Biological Chemistry.
[23] M. Ramirez-Alvarado,et al. Salts enhance both protein stability and amyloid formation of an immunoglobulin light chain. , 2008, Biophysical chemistry.
[24] Jeffrey D. Esko,et al. Heparan sulphate proteoglycans fine-tune mammalian physiology , 2007, Nature.
[25] G. Merlini,et al. Dangerous small B-cell clones. , 2006, Blood.
[26] A. Varki. Nothing in Glycobiology Makes Sense, except in the Light of Evolution , 2006, Cell.
[27] M. Ramirez-Alvarado,et al. The effects of sodium sulfate, glycosaminoglycans, and Congo red on the structure, stability, and amyloid formation of an immunoglobulin light‐chain protein , 2006, Protein science : a publication of the Protein Society.
[28] R. Falk. Diagnosis and Management of the Cardiac Amyloidoses , 2005, Circulation.
[29] P. Adams,et al. Structural basis of light chain amyloidogenicity: comparison of the thermodynamic properties, fibrillogenic potential and tertiary structural features of four Vλ6 proteins , 2004, Journal of molecular recognition : JMR.
[30] Ivan Stamenkovic,et al. Functional structure and composition of the extracellular matrix , 2003, The Journal of pathology.
[31] V. Uversky,et al. Structural transformations of oligomeric intermediates in the fibrillation of the immunoglobulin light chain LEN. , 2003, Biochemistry.
[32] R. Fonseca,et al. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). , 2003, Blood.
[33] M. Schiffer,et al. Factors contributing to decreased protein stability when aspartic acid residues are in β‐sheet regions , 2002, Protein science : a publication of the Protein Society.
[34] V. Uversky,et al. Effect of Association State and Conformational Stability on the Kinetics of Immunoglobulin Light Chain Amyloid Fibril Formation at Physiological pH* , 2002, The Journal of Biological Chemistry.
[35] V. Uversky,et al. Elucidation of the Molecular Mechanism during the Early Events in Immunoglobulin Light Chain Amyloid Fibrillation , 2002, The Journal of Biological Chemistry.
[36] Charles A. Janeway,et al. INAUGURAL ARTICLE by a Recently Elected Academy Member:How the immune system works to protect the host from infection: A personal view , 2001 .
[37] C. Ionescu-Zanetti,et al. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates. , 2001, Biochemistry.
[38] F. Stevens,et al. Immunoglobulin light chains, glycosaminoglycans, and amyloid , 2000, Cellular and Molecular Life Sciences CMLS.
[39] M. Schell,et al. Thermodynamic instability of human lambda 6 light chains: correlation with fibrillogenicity. , 1999, Biochemistry.
[40] M C Manning,et al. Tyrosine, phenylalanine, and disulfide contributions to the circular dichroism of proteins: circular dichroism spectra of wild-type and mutant bovine pancreatic trypsin inhibitor. , 1999, Biochemistry.
[41] R. Falk,et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. , 1998, QJM : monthly journal of the Association of Physicians.
[42] F. Stevens,et al. Interaction between glycosaminoglycans and immunoglobulin light chains. , 1997, Biochemistry.
[43] N. Schormann,et al. Tertiary structure of an amyloid immunoglobulin light chain protein: a proposed model for amyloid fibril formation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[44] M. Hurle,et al. A role for destabilizing amino acid replacements in light-chain amyloidosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[45] M. Pepys,et al. Isolation and characterization of the integral glycosaminoglycan constituents of human amyloid A and monoclonal light-chain amyloid fibrils. , 1991, The Biochemical journal.
[46] V. Trinkaus-Randall,et al. Cellular response of cardiac fibroblasts to amyloidogenic light chains. , 2005, The American journal of pathology.
[47] J. Buxbaum,et al. The systemic amyloidoses. , 1998, The New England journal of medicine.
[48] R. Wetzel. Domain stability in immunoglobulin light chain deposition disorders. , 1997, Advances in protein chemistry.
[49] R. Kyle,et al. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. , 1995, Seminars in hematology.
[50] M. Skinner,et al. Glycosaminoglycans of the hemodialysis-associated carpal synovial amyloid and of amyloid-rich tissues and fibrils of heart, liver, and spleen. , 1990, Clinical chemistry.